This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs

MADISON, N.J., April 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sukumar Nagendran, M.D., has joined Quest Diagnostics as vice president, medical affairs, a new position.

In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services. He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the company's headquarters in Madison, NJ.

"Dr. Nagendran has an impressive record of successful medical affairs in several clinical areas as well as in new product and business development and clinical trial operations," said Dr. Cohen. "These experiences, combined with his relationships with top medical and healthcare experts, will help us to engage medical opinion leaders, payers and clients in more productive dialogues about the composition and value of our services. These competencies are critical as our company strives to be more externally focused and responsive to market needs."

Most recently, Dr. Nagendran served as vice president, head of medical affairs at Reata Pharma. Prior to that, he was therapeutic-area head for new product development, medical affairs, clinical operations and biometrics, in which he oversaw several therapeutic areas, including oncology, cardiovascular disease and diabetes, for Daiichi Sankyo. He has held other senior positions related to clinical development and medical affairs for Pfizer and Novartis. 

Dr. Nagendran also has significant clinical practice experience. Early in his career, Dr. Nagendran practiced in a large internal-medicine physician group and was a staff physician at three hospitals in Phoenix, Arizona. In addition, he is formerly a member of the PrimeCare managed care committee for Phoenix-based Banner Health Systems, one of the largest nonprofit healthcare systems in the United States.

Dr. Nagendran's research on cardiovascular disease, diabetes, oncology, pulmonary medicine and other areas of medicine has been published in a number of peer-reviewed publications, including Endocrine Practice, Current Medical Research & Opinion and Journal of Clinical Lipidology.

Dr. Nagendran earned a bachelor's degree in biochemistry from Rutgers University and earned his doctorate in medicine from UMDNJ-Robert Wood Johnson Medical School in New Jersey, where he was given the Robert Wood Johnson Alumni award for outstanding medical student. He completed his internal medicine training at The Mayo Clinic in Rochester, Minn., and was inducted into the prestigious Mayo Alumni Laureate Group.

About Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.

Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs